Now-Profitable Medivation (MDVN) has XTANDI Approval to Look Forward to; Aegis Keeps at 'Buy'
Tweet Send to a Friend
Aegis Capital reiterates it Buy rating and $125 price target on Medivation, Inc. (Nasdaq: MDVN) following the company's Q4 report ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
